Short answer
Theravance Biopharma, Inc. (TBPH) filed an 8-K current report with the SEC on September 10, 2026 reporting Item 8.01 (Other Events). Merger shareholder vote scheduled for September 18, 2026, making approval the key near-term closing catalyst.
Theravance Biopharma, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Merger shareholder vote scheduled for September 18, 2026, making approval the key near-term closing catalyst
- Three lawsuits and 13 demand letters allege proxy disclosure deficiencies, creating potential delay, litigation costs, or damages
- Company supplements proxy voluntarily while denying wrongdoing, aiming to reduce litigation risk and avoid merger disruption
- Lazard contacted 60 counterparties, with 20 confidentiality agreements and three earlier bids, supporting the board’s sale-process disclosure
- Fairness analysis indicated $15.25–$16.25 per share equity value, based on approximately $385 million net debt and 54.9 million diluted shares
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Theravance Biopharma, Inc. 8-K filings
Get the next TBPH 8-K as it lands
Follow TBPH for push alerts, or ask the research agent what this filing means.